查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405862

美国兽医整形外科市场规模、份额、趋势分析报告：按产品类型、动物类型、应用、给药途径、最终用途、细分市场预测，2024-2030 年

U.S. Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Viscosupplements, Pharmaceuticals), By Animal Type, By Application, By Route Of Administration, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国兽医整形外科市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2024年至2030年美国兽用整形外科药品市场规模将以7.2%的复合年增长率增长，到2030年将达到8.1451亿美元。

这个市场主要是由宠物数量的增长、宠物保险的引入、动物疾病盛行率的上升以及兽医学的进步所推动的。

例如，2023年10月，FDA核准了Librela（bedinvetmab注射液），这是第一个治疗犬类骨关节炎相关疼痛的单株抗体。此外，2022 年 4 月，American Regent, Inc. 的子公司 American Regent Animal Health 获得 FDA核准，可延长 Adequan Canine 和 Adequan im 的保质期。

为了增加在市场上的影响力，兽医整形外科市场的主要企业正在采取产品发布、联盟和收购等策略性倡议，从而推动市场成长。 2022年9月，硕腾收购了Jurox，这是一家专门生产牲畜和伴同性动物动物用药品的私人公司。此次收购于 2021 年 8 月完成，收购范围包括 Jurox 的澳洲业务以及美国、加拿大和英国的区域办事处。这些倡议预计将推动市场成长。

例如，2023 年 10 月，细胞治疗和再生医学公司 Athersys, Inc. (ATHX) 与 Ardent Animal Health 签订了许可协议。透过这项倡议，以重症加护的多干细胞 (invimestrocell) 研究而闻名的 Athersys 进入了动物健康领域。与专注于动物再生医学和癌症治疗的兽医生物技术公司 Ardent 的合作突显了 Athersys 对推动动物医学的承诺。

疫情和相关封锁对市场的主要影响包括成长放缓、销售下降、供应链中断和营运挑战。然而，疫情增加了人们对动物健康和福利的兴趣，加强了宠物父母与动物之间的联繫，并增加了宠物的拥有量。此外，市场医疗率、宠物支出和宠物保险采用率也有所改善。

COVID-19 大流行对兽医部门的其他正面影响包括宠物人性化程度的提高和诊断率的提高。 2021年，市场对动物用药品（包括整形外科药品）的需求和销售均出现成长。 2022年，全球经济景气衰退、成本通膨等宏观经济不确定性对我们的业务产生了负面影响。然而，由于狗和马的整形外科疾病日益流行，由于潜在的市场驱动因素保持不变，预计市场在估计和预测期内将出现显着增长。

美国兽医整形外科市场报告亮点

  • 从产品来看，预计到 2023 年，製药业将占据市场主导地位，份额为 46.72%。针对宠物整形外科疾病的药物治疗，例如非类固醇消炎剂(NSAID) 和止痛药物，被广泛使用并确立为控制疼痛和发炎的有效治疗方法。另一方面，粘胶补充品领域预计在预测期内将以 8.23% 的复合年增长率增长最快。
  • 根据动物类型，市场分为狗和马。狗类细分市场占据主导地位，2023 年占 51.98% 的份额。预计未来 10 年复合年增长率将达到 7.80%。
  • 从应用来看，骨关节炎领域中占最大，2023年将达60.65%。其他细分市场预计在预测期内将以 9.39% 的最快复合年增长率成长。
  • 根据给药途径，市场分为注射剂、口服剂和其他剂型（例如外用剂）。注射剂占据市场主导地位，2023 年份额为 60.40%。其他（主题等）细分市场预计未来 10 年将以 8.22% 的最快复合年增长率成长。
  • 依最终用途划分，兽医院和诊所部门在 2023 年占据最大市场份额，达到 53.59%。预计其他细分市场在预测期内将以 8.68% 的复合年增长率增长最快。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国兽用整形外科药品市场产业展望

  • 市场体系展望
  • 美国兽医整形外科市场动态
  • 市场驱动因素影响分析
  • 市场抑制因素影响分析
  • 市场机会分析
  • 市场问题分析
  • 美国兽医整形外科市场：波特五力分析
  • 美国兽医整形外科市场：PESTEL 分析
  • 宠物饲主人口统计与行为分析
  • COVID-19 大流行、经济衰退和通货膨胀的影响
  • 2018-2030年美国宠物狗和马的估计数量（百万隻）
  • 2022 年接受关节内注射的狗关节估计数量

第 4 章 2018-2030 年产品估算/趋势分析

  • 美国兽医整形外科市场（按产品）：要点
  • 2022年及2030年产品变化分析及市场占有率
  • 副产品
    • 按生技药品
    • 透过药物
  • 生技药品
    • 2018-2030 年生技药品市场估计与预测
    • 干细胞
    • 富含血小板血浆 (Prp)
    • 其他的
  • 黏性补充品
    • 2018-2030 年 Visco补充品市场估计与预测
  • 药品
    • 2018-2030 年医药市场估计与预测
    • 类固醇
    • 边
    • 其他的

第五章 2018-2030年应用预估及趋势分析

  • 美国兽医整形外科市场（按解决方案）：要点
  • 2022年和2030年应用变化分析和市场占有率
  • 按用途
  • 骨关节炎（Oa）
    • 2018-2030 年骨关节炎市场估计与预测
    • 退化性关节疾病
    • 其他的

第六章 2018-2030年给药途径估算及趋势分析

  • 按给药途径的美国兽医整形外科市场：要点
  • 2022年及2030年给药途径变化分析及市场占有率
  • 依给药途径
    • 透过注射
  • 可注射的
    • 2018-2030 年註射剂市场估计与预测
    • 肌肉注射
    • 2018-2030年肌肉注射市场估计与预测
    • 关节内的
    • 2018-2030 年关节内市场估计与预测
    • 其他的
    • 2018-2030 年其他市场估计与预测
  • 口服
    • 2018-2030 年口腔市场估计与预测
  • 其他的
    • 2018-2030 年其他市场估计与预测

第七章 2018-2030年动物种类估算及趋势分析

  • 按动物类型分類的美国兽医整形外科市场：要点
  • 2022年和2030年狗的波动分析和市场占有率
  • 依动物类型
    • 透过狗
  • 狗
    • 2018-2030 年狗市场估计与预测
    • 小型犬品种
    • 中型犬种
    • 大型犬种
  • 马
    • 2018-2030 年马匹市场估计与预测

第 8 章 2018-2030 年最终用途估计与趋势分析

  • 美国兽医整形外科市场（按最终用途）：要点
  • 2022 年和 2030 年最终用途变化分析和市场占有率
  • 按最终用途
  • 兽医医院和诊所
    • 2018-2030 年兽医院和诊所的市场估计和预测
  • 在家里
    • 2018-2030 年家用市场估计与预测
  • 其他的
    • 2018-2030 年其他市场估计与预测

第9章竞争形势

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 策略规划
    • 併购
    • 伙伴关係与协作
    • 其他的
  • 公司简介
    • Zoetis
    • Ardent Animal Health, LLC
    • Enso Discoveries
    • Arthrex, Inc.
    • VetStem, Inc.
    • Contura Vet US
    • MEDREGO LLC
    • PetVivo Holdings, Inc.（Spryng）
    • T-Cyte Therepeutics
    • Boehringer Ingelheim Animal Health USA Inc.
    • American Regent, Inc.
    • Bimeda US
    • Nucleus ProVets

第10章 要点

Product Code: GVR-4-68040-168-1

U.S. Veterinary Orthopedic Medicine Market Growth & Trends:

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys' commitment to advancing veterinary care.

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

U.S. Veterinary Orthopedic Medicine Market Report Highlights:

  • Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period
  • Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade
  • Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period
  • Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade
  • On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information/data Analysis
    • 1.4.1 Information Analysis
  • 1.5 Market Formulation & Visualization
  • 1.6 Data Validation & Publishing
  • 1.7 Model Details
    • 1.7.1 Approach 1: Commodity Flow Analysis
      • 1.7.1.1 Hybrid Market Estimation Model
    • 1.7.2 Global Market: Cagr Calculation
    • 1.7.3 Approach 2: Parent Market Analysis
  • 1.8 List Of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Veterinary Orthopedic Medicine Market Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Analysis
  • 3.2 U.S. Veterinary Orthopedic Medicine Market Dynamics
  • 3.3 Market Driver Impact Analysis
    • 3.3.1 Increasing Incidence Of Orthopedic Problems
    • 3.3.2 Growing Uptake Of Pet Insurance
    • 3.3.3 Increase In Canine & Equine Population
    • 3.3.4 Advancements In Veterinary Orthopedic Medicine
    • 3.3.5 Supportive Initiatives
  • 3.4 Market Restraint Impact Analysis
    • 3.4.1. High Cost Of Treatment
  • 3.5 Market Opportunity Analysis
  • 3.6 Market Challenge Analysis
  • 3.7 U.S. Veterinary Orthopedic Medicine Market: Porter's 5 Forces Analysis
    • 3.7.1 Bargaining Power Of Buyers: High
    • 3.7.2 Bargaining Power Of Suppliers: Moderate - Low
    • 3.7.3 Threat Of New Entrants: High
    • 3.7.4 Threat Of Substitutes: Low - Moderate
    • 3.7.5 Competitive Rivalry: High
  • 3.8 U.S. Veterinary Orthopedic Medicine Market: Pestel Analysis
    • 3.8.1 Political
    • 3.8.2 Economic
    • 3.8.3 Social
    • 3.8.4 Technological
    • 3.8.5 Environmental
    • 3.8.6 Legal
  • 3.9 Pet Owner Demographics & Behavior Analysis
  • 3.10 Impact Of Covid-19 Pandemic, Recession & Inflation
  • 3.11 U.S. Estimated Pet Dog & Horse Population (Million), 2018 To 2030
  • 3.12 Estimated Number Of Intra-articularly Injected Canine Joints, 2022

Chapter 4 Product Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 4.1 U.S. Veterinary Orthopedic Medicine Market By Product: Key Takeaways
  • 4.2 Product Movement Analysis & Market Share, 2022 & 2030
  • 4.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Product (USD Million)
    • 4.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Biologics (USD Million)
    • 4.3.2 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Pharmaceuticals (USD Million)
  • 4.4 Biologics
    • 4.4.1 Biologics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2 Stem Cells
      • 4.4.2.1 Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3 Platelet-rich Plasma (Prp)
      • 4.4.3.1 Platelet-rich Plasma (Prp) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4 Other Biologics
      • 4.4.4.1 Other Biologics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.5 Viscosupplements
    • 4.5.1 Viscosupplements Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.6 Pharmaceuticals
    • 4.6.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2 Steroids
      • 4.6.2.1 Steroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3 Nsaids
      • 4.6.3.1 Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4 Others
      • 4.6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Application Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 5.1 U.S. Veterinary Orthopedic Medicine Market By Solutions: Key Takeaways
  • 5.2 Application Movement Analysis & Market Share, 2022 & 2030
  • 5.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Application (USD Million)
  • 5.4 Osteoarthritis (Oa)
    • 5.4.1 Osteoarthritis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2 Degenerative Joint Disease
      • 5.4.2.1 Degenerative Joint Disease Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3 Others
      • 5.4.3.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Route Of Administration Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 6.1 U.S. Veterinary Orthopedic Medicine Market By Route Of Administration: Key Takeaways
  • 6.2 Route Of Administration Movement Analysis & Market Share, 2022 & 2030
  • 6.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Route Of Administration (USD Million)
    • 6.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Injectable (USD Million)
  • 6.4 Injectable
    • 6.4.1 Injectable Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2 Intra-muscular
    • 6.4.3 Intra-muscular Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4 Intra-articular
    • 6.4.5 Intra-articular Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6 Others
    • 6.4.7 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5 Oral
    • 6.5.1 Oral Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Animal Type Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 7.1 U.S. Veterinary Orthopedic Medicine Market, By Animal Type: Key Takeaways
  • 7.2 Dogs Movement Analysis & Market Share, 2022 & 2030
  • 7.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Animal Type (USD Million)
    • 7.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Dogs (USD Million)
  • 7.4 Dogs
    • 7.4.1 Dogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Small Breeds
      • 7.4.2.1 Small Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Medium-sized Breeds
      • 7.4.3.1 Medium-sized Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Large Breeds
      • 7.4.4.1 Large Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Horses
    • 7.5.1 Horses Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 End-use Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 8.1 U.S. Veterinary Orthopedic Medicine Market By End-use: Key Takeaways
  • 8.2 End-use Movement Analysis & Market Share, 2022 & 2030
  • 8.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts By End-use (USD Million)
  • 8.4 Veterinary Hospitals & Clinics
    • 8.4.1 Veterinary Hospitals & Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5 At-home
    • 8.5.1 At-home Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6 Others
    • 8.6.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Strategy Mapping
    • 9.3.1. Mergers & Acquisitions
    • 9.3.2. Partnerships & Collaborations
    • 9.3.3. Others
  • 9.4. Company Profiles
    • 9.4.1. Zoetis
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Ardent Animal Health, LLC
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Enso Discoveries
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Arthrex, Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. VetStem, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Contura Vet US
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. MEDREGO LLC
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. PetVivo Holdings, Inc. (Spryng)
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. T-Cyte Therepeutics
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Boehringer Ingelheim Animal Health USA Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. American Regent, Inc.
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. Bimeda U.S.
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Strategic Initiatives
    • 9.4.13. Nucleus ProVets
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Strategic Initiatives

Chapter 10. Key Takeaways

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Impact of COVID-19, recession, & inflation on some key players
  • Table 3 U.S. veterinary orthopedic medicine market estimates and forecast, by product, 2018 - 2030 (USD million)
  • Table 4 U.S. veterinary orthopedic medicine market estimates and forecast, by Biologics, 2018 - 2030 (USD million)
  • Table 5 U.S. veterinary orthopedic medicine market estimates and forecast, by Pharmaceuticals, 2018 - 2030 (USD million)
  • Table 6 U.S. veterinary orthopedic medicine market estimates and forecast, by application, 2018 - 2030 (USD million)
  • Table 7 U.S. veterinary orthopedic medicine market estimates and forecast, by route of administration, 2018 - 2030 (USD million)
  • Table 8 U.S. veterinary orthopedic medicine market estimates and forecast, by injectable, 2018 - 2030 (USD million)
  • Table 9 U.S. veterinary orthopedic medicine market estimates and forecast, by animal type, 2018 - 2030 (USD million)
  • Table 10 U.S. veterinary orthopedic medicine market estimates and forecast, by dogs, 2018 - 2030 (USD million)
  • Table 11 U.S. veterinary orthopedic medicine market estimates and forecast, by end-use, 2018 - 2030 (USD million)
  • Table 12 Participants' overview
  • Table 13 Financial performance
  • Table 14 Products benchmarking
  • Table 15 Key companies undertaking acquisitions.
  • Table 16 Key companies launching new products.
  • Table 17 Key companies undertaking partnership & collaboration strategies.
  • Table 18 Key market players initiating expansion.

List of Figures

  • Fig. 1 U.S. Veterinary Orthopedic Medicine Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation and Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for commodity flow analysis of animal health market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent Market Analysis, 2023 (USD million)
  • Fig. 16 Ancillary market outlook, 2023
  • Fig. 17 U.S. Veterinary Orthopedic Medicine Market Dynamics
  • Fig. 18 U.S. Veterinary Orthopedic Medicine Market: PORTER's analysis
  • Fig. 19 U.S. Veterinary Orthopedic Medicine Market: PESTEL analysis
  • Fig. 20 U.S. Veterinary Orthopedic Medicine Market by product: Key takeaways
  • Fig. 21 U.S. Veterinary Orthopedic Medicine Market by Product, Market share, 2023 & 2030
  • Fig. 22 Biologics market, 2018 - 2030 (USD million)
  • Fig. 23 Stem cells market, 2018 - 2030 (USD million)
  • Fig. 24 PRP market, 2018 - 2030 (USD million)
  • Fig. 25 Other biologics market, 2018 - 2030 (USD million)
  • Fig. 26 Viscosupplements market, 2018 - 2030 (USD million)
  • Fig. 27 Pharmaceuticals market, 2018 - 2030 (USD million)
  • Fig. 28 Steroids market, 2018 - 2030 (USD million)
  • Fig. 29 NSAIDS market, 2018 - 2030 (USD million)
  • Fig. 30 Others market, 2018 - 2030 (USD million)
  • Fig. 31 U.S. veterinary orthopedic medicine market by application: Key Takeaways
  • Fig. 32 U.S. veterinary orthopedic medicine market by application, market share, 2023 & 2030
  • Fig. 33 Osteoarthritis market, 2018 - 2030 (USD million)
  • Fig. 34 Degenerative joint disease market, 2018 - 2030 (USD million)
  • Fig. 35 Platelet-Rich Plasma (PRP) market, 2018 - 2030 (USD million)
  • Fig. 36 U.S. veterinary orthopedic medicine market by route of administration: Key Takeaways
  • Fig. 37 U.S. veterinary orthopedic medicine market by route of administration, market share, 2023 & 2030
  • Fig. 38 Injectable market, 2018 - 2030 (USD million)
  • Fig. 39 Intra-Muscular market, 2018 - 2030 (USD million)
  • Fig. 40 Intra-Articular market, 2018 - 2030 (USD million)
  • Fig. 41 Others market, 2018 - 2030 (USD million)
  • Fig. 42 Oral market, 2018 - 2030 (USD million)
  • Fig. 43 Others market, 2018 - 2030 (USD million)
  • Fig. 44 U.S. veterinary orthopedic medicine market, by animal type: Key takeaways
  • Fig. 45 U.S. veterinary orthopedic medicine market, by animal type: Market share, 2023 & 2030
  • Fig. 46 Dogs market, 2018 - 2030 (USD million)
  • Fig. 47 Small breeds market, 2018 - 2030 (USD million)
  • Fig. 48 Medium-sized breeds market, 2018 - 2030 (USD million)
  • Fig. 49 Large breeds market, 2018 - 2030 (USD million)
  • Fig. 50 Horses market, 2018 - 2030 (USD million)
  • Fig. 51 U.S. veterinary orthopedic medicine market, by end-use: Key takeaways
  • Fig. 52 U.S. veterinary orthopedic medicine market, by end-use, market share, 2023 & 2030
  • Fig. 53 Veterinary hospitals & clinics market, 2018 - 2030 (USD million)
  • Fig. 54 At-home market, 2018 - 2030 (USD million)
  • Fig. 55 Others market, 2018 - 2030 (USD million)
  • Fig. 56 Market Participant categorization
  • Fig. 57 Strategic Framework